Trial Profile
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573 in Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Aug 2020
Price :
$35
*
At a glance
- Drugs Belvarafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Hanmi Pharmaceutical
- 06 Aug 2020 Status changed from active, no longer recruiting to completed.
- 04 Jun 2019 Results of overall safety and efficacy findings from 2 phase I studies NCT02405065, NCT03118817 presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 05 Feb 2017 Planned End Date changed from 31 Dec 2016 to 1 Sep 2017.